| # | Drug | Count |
|---|---|---|
| 0 | OSIMERTINIB | 281 |
| 1 | BEVACIZUMAB | 203 |
| 2 | CARBOPLATIN | 199 |
| 3 | PACLITAXEL | 171 |
| 4 | PACLITAXEL (AIBUMIN-BOUND) | 147 |
| 5 | METHOTREXATE SODIUM | 145 |
| 6 | DEXAMETHASONE | 138 |
| 7 | DEXAMETHASONE 1.5 MG | 138 |
| 8 | METHOTREXATE | 137 |
| 9 | TRASTUZUMAB | 136 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FLUOROESTRADIOL F 18 | 1 | 0.0769 |
| 1 | ACETAMINOPHEN, DEXBROMPHENIRAMINE MALEATE | 1 | 0.0156 |
| 2 | GEFITINIB | 117 | 0.0131 |
| 3 | AFATINIB | 80 | 0.0123 |
| 4 | CERITINIB | 29 | 0.0123 |
| 5 | OSIMERTINIB | 281 | 0.0096 |
| 6 | DEMECLOCYCLINE | 2 | 0.0090 |
| 7 | TUCATINIB | 48 | 0.0074 |
| 8 | TAFASITAMAB-CXIX | 5 | 0.0058 |
| 9 | ZOLBETUXIMAB | 5 | 0.0056 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 668 |
| 1 | Platinum-based Drug [EPC] | 319 |
| 2 | Corticosteroid [EPC] | 262 |
| 3 | Microtubule Inhibitor [EPC] | 246 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 210 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 209 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 204 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 188 |
| 8 | Alkylating Drug [EPC] | 171 |
| 9 | HER2/neu Receptor Antagonist [EPC] | 136 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 5 | 0.0056 |
| 1 | Nucleoside Analog Antifungal [EPC] | 4 | 0.0032 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 17 | 0.0028 |
| 3 | Actinomycin [EPC] | 6 | 0.0028 |
| 4 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0021 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 136 | 0.0018 |
| 6 | Microtubule Inhibitor [EPC] | 246 | 0.0018 |
| 7 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 5 | 0.0017 |
| 8 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 29 | 0.0015 |
| 9 | Estrogen Receptor Antagonist [EPC] | 55 | 0.0014 |